Administration costs of intravenous biologic drugs for rheumatoid arthritis

SpringerPlus

Table 2 Administration and total costs (€2011) by the indicated common and non-indicated adult RA dose

Drug	RA dose	Administration (€, N 82) per infusion				Total costs^a(€, N 106) per infusion
		N	*Average*	*S.D.*	*Range*	N	*Average*	*S.D.*	*Range*
Infliximab	Yes	11^bc	355.91	125.45	123–543	10^ef	2243.10	110.92	1990–2410
Infliximab	No	41^b	324.15	166.69	25–728	41^e	3344.09	1673.13	647–6648
Rituximab	Yes	6^cd	561.21	516.78	142–1572	6^fg	3619.17	516.78	3200–4630
Rituximab	No	14^d	586.37	402.34	15–1560	14^g	2180.88	1463.94	342–6147
Abatacept	Yes	1	334.00	NS	NS	1	1450.00	NS	NS
Abatacept	No	4	486.00	138.97	376–688	4	1416.00	507.83	1120–2176
Tocilizumab	Yes	1	293.96	NS	NS	1	2176.00	NS	NS
	No	4	444.80	219.86	263–728	4	1273.50	117.91	1204–1450

RA = rheumatoid arthritis. N = number of observations. S.D. = standard deviation. NS = not stated. ^a Includes administration and drug costs. ^b IFX using RA dose did not have significantly lower administration costs compared with IFX not using RA dose. ^c RTX with RA dose was not significantly more costly compared with IFX with RA dose. ^d RTX using RA dose did not have significantly lower administration costs compared with RTX patients using RA dose. ^e IFX patients using RA dose had significantly lower total costs compared with IFX patients not using RA dose (p-value = 0.013). ^f RTX patients using RA dose had significantly lower total costs compared with RTX patients not using RA dose (p-value = 0.011). ^g RTX with RA dose was significantly more costly compared with IFX with RA dose (p-value = 0.001).